Experience: Expertise in Translational Tumor Immunotherapy with a focus in stage IV melanoma, advanced prostate cancer, Renal Cell Carcinoma, NSCLC and breast cancer, Multiple Myeloma. Expert in Oncology, Translational Medicine, Surgical Oncology, Immunology, Clinical Development, Medical Affairs, early and late-stage drug development, Biotechnology. Goals: Driving new assets and immune monitoring modalities to establish immunotherapy strategies and platforms as the new foundation of care in tumor therapy. Educate HCPs, physicians and patients about the benefits to harness the patients immune system to treat cancer. Developing new combination therapy paradigms combining classic tumor treatments and sequencing with tumor vaccines, immune checkpoint modulators and new tumor and immune modulation assets.

Senior Global Clinical Leader, LCM Xofigo (Radium-223 Chloride) Multiple Myeloma @ From July 2014 to Present (1 year 6 months) Senior Global Medical Affairs Lead, Head, Stivarga, Oncology @ Senior Global Medical Affairs Lead, Head for Stivarga program (regorafenib) and Combinations, LCM, MAP, NIS, ISS From September 2013 to July 2014 (11 months) Medical Director, Global Medical Affairs, Immuno-Oncology @ Global Medical Lead Nivolumab (BMS-936558; anti-PD-1) for Melanoma and RCC From April 2012 to September 2013 (1 year 6 months) Medical Director, Clinical & Medical Affairs @ 09/2011 – present (Global) Medical Director, Clinical & Medical Affairs 04/2010 – 09/2011 (Global) Medical Director, Medical Affairs Responsibilities/ Accomplishments: o Phase III/IV LCM of Provenge; Lead, global phase III study (P10-4 ACTION) evaluating sipuleucel-T in M1 ADPC patient population (n=1600+); final protocol accepted by FDA and EMEA after parallel scientific review 08/2011; Trial design published at ASCO 2011 o Lead, Investigator-initiated trial program; focus on combination therapies (immune checkpoints, new agents, XRT/SBRT, CTx) o Lead, development of umbrella immune monitoring protocol o Lead, product integrity task force; specific on-site support for new customers regarding leukapheresis, final product handling and experience; o Lead, development of Phase II combination study designs and protocols for Provenge with new anti-androgen assets. o Lead, bridging Immune Monitoring and Clinical & Medical Affairs Departments; o Life Cycle Management Planning team; strategic competitive landscape analysis for treatment of prostate cancer o Member of the Drug Safety Committee o Member of Business Development team, expertise on vaccines, immune modulatory agents, autologous and allogenic cellular therapies, new anti-androgens. o KOL development, global, focus on GU Oncologists, Urologists, Translational Immunotherapy specialists; o Clinical/Medical educational support, MSLs, Marketing, Sales, Publications. o Close project relationships with regulatory and drug safety leads. o Planning and execution of medical and translational advisory boards. o Rotational member of the PRC/SMRC review committee; o Clinical/Medical representation and member of ASCO, ASCO-GU, AUA, EAU, SIU, ECCO/ESMO, SITC, AACR annual meetings From April 2010 to April 2012 (2 years 1 month) Senior Scientist, Translational Tumor Immunotherapy, Faculty Member @ 2010 – present Consultant, Advisor for clinical trials and translation of selective T cell depletion into the clinic for the Laboratory of Molecular & Tumor Immunology, Ongoing Phase I/II trials in stage IV melanoma and mCRPC. 2008 – 2010 Management of independent research laboratory and personnel, focusing on translation of intervention therapies to modulate and control tumor-induced regulatory T cells and enhance therapeutic efficacy and immune responses in stage IV melanoma. 2007 – 2010 Protocol development and establishment of GMP level processing of leukopheresis products, selective magnetic depletion of T cell subsets (CD25 GMP) using the Miltenyi CliniMacs system, cryo-preservation of the product and on-site re-infusion after induction of non-myeloablative chemotherapy-induced lymphopenia. Drafting IND application to the FDA. Focus on stage IV melanoma and metastatic, castrate- resistant prostate cancer (mCRPC) using autologous tumor vaccine or GVAX respectively. Co-developed Phase I/II translational trials for both indications and initiated both trials. 2006 – 2008 Planning, development and establishment of the new Providence Cancer Center vivarium. Planning and successful transfer of all murine strains into the new vivarium 2006 – 2009 Planning and establishment of the Video Conferencing Center at the Earle A. Chiles Research Institute (Budget: $500K); helped to integrate two VC bridges in WA and OR to interconnect all internal Providence and external national and international sites. 2005 – Present Use Patent filed – pending for the use of CD25-depletion and manipulation of tumor-induced regulatory T cells in the reconstituted, lymphopenic host (Co-Inventor). 2005 – 2010 Chair, Institutional Animal Care and Use Committee (IACUC). From July 1999 to April 2010 (10 years 10 months) Surgical Resident @ Residency, Surgical Clinic and Policlinic, Technical University, Klinikum Rechts der Isar, Munich, Germany. Focus: Surgical Oncology, Transplant Surgery, Trauma From January 1998 to July 1999 (1 year 7 months)

Certificate, Human Investigations @ Oregon Health & Science University From 2008 to 2010 Doctor of Medicine (M.D.), Immunology, Xenotransplantation, summa cum laude @ Ludwig-Maximilians Universität München / LMU Munich From 1992 to 1998 Doctor of Medicine (M.D.), Medicine, focus Surgery @ Ludwig-Maximilians Universität München / LMU Munich From 1990 to 1997 Abitur, Best of class 1989 @ Carl-Spitzweg Gymnasium From 1980 to 1989 Christian MD is skilled in: Cancer, Oncology, Clinical Trials, Immunotherapy, Immunology, Drug Development, Clinical Development, Biotechnology, Drug Discovery, Flow Cytometry, Lifesciences, Molecular Biology, Medical Affairs, Early and late-stage drug development, Translational Research